(NASDAQ: ORGO) Organogenesis Holdings's forecast annual revenue growth rate of 14.29% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 274.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.91%.
Organogenesis Holdings's revenue in 2025 is $458,760,000.On average, 4 Wall Street analysts forecast ORGO's revenue for 2025 to be $62,683,406,279, with the lowest ORGO revenue forecast at $60,156,483,842, and the highest ORGO revenue forecast at $64,600,163,208. On average, 4 Wall Street analysts forecast ORGO's revenue for 2026 to be $78,637,775,502, with the lowest ORGO revenue forecast at $65,229,356,747, and the highest ORGO revenue forecast at $92,011,943,802.
In 2027, ORGO is forecast to generate $86,743,716,452 in revenue, with the lowest revenue forecast at $70,935,228,796 and the highest revenue forecast at $102,587,723,099.